Beactica is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. We offer expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using our proprietary Sprint™ platform.
Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes.
